Effect of xenon on catecholamine and hemodynamic responses to surgical noxious stimulation in humans

Kobayashi, Shunji; Katoh, Takasumi; Bito, Hiromichi; Sato, Shigehito

doi:10.1016/j.jclinane.2005.12.007

Cited by 2 publications

(1 citation statement)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To rule out a species-specific effect, we lack alternative reports on catecholamine concentrations during xenon/opioid anesthesia in dogs. Potent analgesic properties of xenon have been advocated to contribute to a reduction of serum adrenaline concentrations in pentobarbitone-anesthetized pigs (24) and patients receiving nitrous oxide (18) or sevoflurane anesthesia (25). This mechanism may, however, rely on pain-related elevations of catecholamines and, therefore, may be significantly less effective when xenon is combined with a potent analgesic, for example, remifentanil, such as in the present study.…”

Section: Plasma Hormonesmentioning

confidence: 74%

Xenon/Remifentanil Anesthesia Protects Against Adverse Effects of Losartan on Hemodynamic Challenges Induced by Anesthesia and Acute Blood Loss

Francis

Philippi-Höhne

Klein³

et al. 2010

Shock

View full text Add to dashboard Cite

The authors aimed to test the hypothesis that xenon anesthesia limits adverse hypotensive effects of losartan during acute hemorrhage. In six conscious unsedated Beagle dogs, the systemic and pulmonary circulation were monitored invasively, and two subsequent 60-min hypotensive challenges were performed by (a) induction (propofol) and maintenance of anesthesia with isoflurane/remifentanil or xenon/remifentanil and by (b) subsequent hemorrhage (20 mL kg⁻¹ within 5 min) from a central vein. The same amount of blood was retransfused 1 h after hemorrhage. Experiments were performed with or without acute angiotensin II receptor subtype 1 blockade by i.v. losartan (100 μg·kg⁻¹·min⁻¹) starting 45 min before induction of anesthesia. Four experiments were performed in each individual dog. Xenon/remifentanil anesthesia provided higher baseline mean arterial blood pressure (85 ± 6 mmHg) than isoflurane/remifentanil anesthesia (67 ± 3 mmHg). In losartan-treated animals, isoflurane/remifentanil caused significant hypotension (42 ± 4 mmHg for isoflurane/remifentanil vs. 71 ± 6 mmHg for xenon/remifentanil). Independent of losartan, hemorrhage did not induce any further reduction of mean arterial blood pressure or cardiac output in either group. Spontaneous hemodynamic recovery was observed in all groups before retransfusion was started. Losartan did not alter the adrenaline, noradrenaline, and vasopressin response to acute hemorrhage. Losartan potentiates hypotension induced by isoflurane/remifentanil anesthesia but does not affect the hemodynamic stability during xenon/remifentanil anesthesia. Losartan does not deteriorate the hemodynamic adaptation to hemorrhage of 20 mL kg⁻¹ during xenon/remifentanil and isoflurane/remifentanil anesthesia. Therefore, xenon/remifentanil anesthesia protects against circulatory side effects of losartan pretreatment and thus may afford safer therapeutic use of losartan during acute hemorrhage.

show abstract

Section: Plasma Hormonesmentioning

confidence: 74%